SCYX vs. PRQR, CRDF, CGEN, ACRS, SLN, CYBN, SCPH, GNFT, ACRV, and LYEL
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Compugen (CGEN), Aclaris Therapeutics (ACRS), Silence Therapeutics (SLN), Cybin (CYBN), scPharmaceuticals (SCPH), Genfit (GNFT), Acrivon Therapeutics (ACRV), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.
SCYNEXIS vs.
SCYNEXIS (NASDAQ:SCYX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.
In the previous week, ProQR Therapeutics had 4 more articles in the media than SCYNEXIS. MarketBeat recorded 4 mentions for ProQR Therapeutics and 0 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.89 beat ProQR Therapeutics' score of 0.48 indicating that SCYNEXIS is being referred to more favorably in the media.
SCYNEXIS received 173 more outperform votes than ProQR Therapeutics when rated by MarketBeat users. Likewise, 70.04% of users gave SCYNEXIS an outperform vote while only 61.71% of users gave ProQR Therapeutics an outperform vote.
SCYNEXIS has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
ProQR Therapeutics has a net margin of -134.31% compared to SCYNEXIS's net margin of -425.41%. SCYNEXIS's return on equity of -66.21% beat ProQR Therapeutics' return on equity.
ProQR Therapeutics has a consensus target price of $8.83, indicating a potential upside of 272.71%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than SCYNEXIS.
SCYNEXIS has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 2.9% of SCYNEXIS shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
ProQR Therapeutics beats SCYNEXIS on 10 of the 19 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SCYNEXIS Competitors List
Related Companies and Tools
This page (NASDAQ:SCYX) was last updated on 1/18/2025 by MarketBeat.com Staff
Free SCYX Stock Alerts